INTRODUCTION
Skeletal muscle is the major reservoir of body protein, and exhibits very high plasticity in its ability to adapt to changing functional demands. The loss of muscle proteins with reduced muscle activity, malnutrition, metabolic disease, or aging is a universal phenomenon, known as "muscle atrophy" or "wasting" (Jagoe and Goldberg, 2001) . The structural and functional consequences of all forms of atrophy are reduced muscle mass and fiber cross-sectional area, reduced contractile force, and increased fatigability and insulin resistance (Booth and Thomason, 1991) .
The increased degradation of proteins during skeletal muscle atrophy is commonly coupled to the activation of the ubiquitin-dependent protease pathway. Ubiquitinated proteins are degraded by muscle-specific ubiquitin ligases (Bodine et al., 2001; Tesseraud et al., 2007) . Previous studies have suggested that the transcriptional regulation of the E3 protein ligases, atrogin-1/muscle atrophy F-box (MAFbx) and muscle-specific RING finger 1 (MuRF1), is elevated in skeletal muscle and is involved in the initiation and development of skeletal muscle atrophy (Glass, 2005) . The expression of MAFbx and MuRF1 is increased in models of skeletal muscle atrophy that involve fasting, denervation, glucocorticoid treatment, or cast immobilization (Gomes et al., 2001; Wray et al., 2003; Li et al., 2005; Tobimatsu et al., 2009) . MAFbx expression was elevated in serum-starved skeletal muscle cells (Schulze et al., 2005) . The expression of MuRF1 increases in cardiac cells in serum-free medium (Skurk et al., 2005) . It has been suggested that MuRF1 is involved in the degradation of functional intracellular proteins, such as troponin I and titin, by their ubiquitination (McElhinny et al., 2002; Kedar et al., 2004) . These results indicate that MuRF1 may be used as a marker of skeletal muscle atrophy in the diagnosis and treatment of related diseases.
Insulin-like growth factor 1 induces an increase in muscle mass via the Akt pathway and causes the activation of downstream signals that participate in protein synthesis. Moreover, skeletal muscle atrophy is coupled to the diminution of Akt activation (Sugita et al., 2005) , and Akt inhibits the expression of MuRF1 in atrophic muscle (Sandri et al., J Kim, et al 2004) . Mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinase (ERK) 1/2, p38 MAPK and c-Jun N-terminal kinase (JNK), play important roles in a variety of cells (Lee et al., 2007; Lee et al., 2009) . MAPKs are also involved in skeletal muscle atrophy. It has been reported that p38 MAPK activity triggers the development of tumor necrosis factor α-induced, hindlimb-suspensioninduced, and immobilization-induced atrophy in skeletal muscle (Hilder et al., 2003; Machida and Booth, 2005) . ERK1/2 is involved in the increase in muscle mass and the diminution of MuRF expression (Shi et al., 2009) . Moreover, p38 MAPK activity is regulated by Akt in a variety of cells (Yamamoto et al., 2008) . It has been suggested that the induction of MAFbx and MuRF1 in atrophied muscle is mediated by the Akt and nuclear factor-κB pathways, respectively (McKinnell and Rudnicki, 2004; Nader, 2005) . However, in skeletal muscle, the function of p38 MAPK during cast-immobilization-induced atrophy, and especially in MuRF1 expression, is not yet understood.
Because both MuRF1 and p38 MAPK are important mediators of skeletal muscle atrophy, we hypothesized in this study that the two molecules and their functional interaction are closely involved in the reduction of muscle mass caused by cast immobilization in the rat gastrocnemius muscle. To test this hypothesis, we investigated the effect of p38 MAPK on the expression of MuRF1 in cast-immobilized rat gastrocnemius muscles. The results were confirmed in serum-starved rat L6 skeletal myoblasts.
METHODS

M aterials
Anti-p38 MAPK and anti-Akt antibodies were purchased from Cell Signaling (MA, USA). Anti-MuRF1 antibody was purchased from Santa Cruz Biotechnology (CA, USA). Anti-β-actin antibody was purchased from Sigma (MO, USA). SB203580 was purchased from Tocris Cookson Ltd (UK).
Animals and cast immobilization
Our investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) . All experiments and animal care also conformed to the institutional guidelines established by Konkuk University, Korea. All the animals were housed in a temperature-and humidity-controlled room under a 12-h light/dark cycle and were fed a standard commercial chow, with ad libitum access to both food and water. Male Sprague Dawley rats (190∼200 g; Orient Bio, Korea) were anesthetized with an intramuscular injection of ketamine hydrochloride (35 mg/kg) mixed with xylazine hydrochloride (5 mg/kg) before the attachment of a plaster of Paris casting material (Booth and Kelso, 1973) .
M easurement of morphological changes
The isolated gastrocnemius muscles were stained with hematoxylin and eosin (H&E) for general histology or incubated with the appropriate fluorescently labeled secondary antibodies (Vectastain universal elite ABC Kit, Vector Laboratories, CA, USA). The samples were mounted on glass slides and the images were captured under a confocal microscope system (FV-1000 spectral, Olympus, Japan). The muscle size was measured using Fluoview software (FV10-ASW, Olympus) and is expressed as the total muscle cell area.
Transfection of MuRF1 siRNA and measurement of cell size
Rat L6 skeletal myoblasts ( 1×10 5 ) from the American Type Culture Collection (MD, USA) were cultured in 60 mm tissue-culture dishes were replenished with FBS-free DMEM and then transfected with small interfering RNA (siRNA) or nonsilencing control MuRF1 siRNA to a final concentration of 500 pM siRNA using a transfection reagent (WelFect-Q TM Gold, Welgene, Korea). The relative expression levels of MuRF1 were examined using immunoblotting analysis with an antibody directed against MuRF1 and β-actin. Two siRNAs were designed to target the rat MuRF1 sequences 5'-UCUCACUCAAAGGCCUAGA-3' (siRNA 1, accession number NM_1775283; Bioneer, Korea) and 5'-CACGAAGACGAGAAAAUCA-3' (siRNA 2, accession number NM_1775284; Bioneer). The nonsilencing control siRNA was purchased from Bioneer. The morphological changes in the cells were visualized with a phase-contrast microscope (DCR-DVD803 NTSC, Carl Zeiss, Japan) and measured with Scion Image 4.03 (Scion Co., MA, USA). The results are given as the area-to-square ratio.
Immunoblotting
Immunoblotting was performed as previously described (Lee et al., 2007; Lee et al., 2009 ).
Data analysis
The data are expressed as means± standard errors (SE) of the means. The data were statistically evaluated with Student's t test for the comparisons of pairs of groups and with analysis of variance (ANOVA) for multiple comparisons. A p value of ＜0.05 was considered statistically significant.
RESULTS
Cast-immobilization-induced morphological changes in rat gastrocnemius muscle
Firstly, we confirmed the effects of cast immobilization, which induces muscle atrophy. The total weight of the gastrocnemius muscle was significantly diminished in rats at day 14 after cast immobilization compared with that of noncasted control rats (0.51 ± 0.046 g vs 1.47 ± 0.061 g, respectively, n=8; Fig. 1A ). Similar results were observed for the ratio of the weight of the gastrocnemius muscle to body weight (Fig. 1B) . To confirm whether cast immobilization of the limb affects the atrophic response in the rat gastrocnemius muscle, the cross-sectional areas were compared in noncasted and casted gastrocnemius muscles using H&E staining. The cross-sectional areas of the muscle fibers from the cast-atrophic muscles were markedly less than those of the noncasted control group (426.9±4.08 vs 761.2±6.36 μm 2 , respectively, n=7; Fig. 1C ).
MuRF1 expression is closely related to skeletal muscle atrophy. Therefore, changes in the expression of MuRF1 , n=8) , ratios of muscle weight to body weight (B, n=8), and cross-sectional areas (C, n=7) were measured 14 days after cast immobilization. The muscle fibers were visualized with H&E staining, as described in the Materials and methods. (D) Immunohistological analysis of rats at day 14 after cast immobilization. MuRF1 expression (red) was visualized with a phasecontrast microscope (×400). Representative result of six independent experiments. *Significantly different from the noncasted control (p＜0.05).
Fig. 2.
Expression of MuRF1 and p38 MAPK in gastrocnemius muscles from cast-immobilized rats. Immunoblotting analysis of MuRF1 (A) and p38 MAPK (B) in the gastrocnemius muscle. Protein expression and phosphorylation were examined using anti-nonphospho-and anti-phosphospecific antibodies, respectively. The statistical results were obtained from the upper panels. The levels of MuRF1 expression and p38 MAPK phosphorylation in the noncasted muscle group were considered to be 100% (n=4). *Significantly different from the noncasted controls (p＜0.05). Non, noncasted.
were determined in casted and noncasted rat gastrocnemius muscles. In a fluorescence study, MuRF1 expression was observed in both noncasted and casted gastrocnemius muscles at day 14 but was greater in the casted group than in the noncasted group (Fig. 1D) . Immunoblotting analysis showed that the expression of MuRF1 was increased in the gastrocnemius muscles from cast immobilization group compared with that in the noncasted controls (207.3±40.9% of noncasted control group, n=4; Fig. 2A ). To clarify the involvement of p38 MAPK in the elevated expression of MuRF1 in response to cast immobilization , the phosphorylation of p38 MAPK was measured in the gastrocnemius muscle. As shown in Fig. 2B , the phosphorylation of p38 MAPK in the gastrocnemius muscle was significantly increased at day 14 in the hindlimb cast group compared with that in the noncasted control group (216.2±53.3% of the noncasted control, n=4). However, the cast did not influence the total expression levels of β-actin or p38 MAPK in either group (Fig. 2) .
Properties of L6 myoblasts during serum starvation
Previous studies have suggested that serum starvation can be used as a cellular model of the atrophy of skeletal muscle caused by cast immobilization. Therefore, the effects of serum starvation on cell sizes were determined. The cells gradually diminished in size during serum starvation in a time-dependent manner (Fig. 3A) . The increases in MuRF1 expression observed in cast-immobilized skeletal muscles were confirmed in L6 myoblasts cultured in serum-free medium. The expression of MuRF1 was significantly increased in serum-starved L6 myoblasts (Fig. 3B) . Serum starvation of cells significantly increased the phosphorylation of p38 MAPK (Fig. 3C) . However, the starvation did not influence the total expression levels of p38 MAPK, β-actin or MuRF1 in either group (Fig. 3) .
To confirm the role of MuRF1 in atrophied muscle cells, we tested the effects of MuRF1 in L6 myoblasts treated with MuRF1 siRNA. Transfection of L6 myoblasts with MuRF1 siRNA reduced the expression of MuRF1 during L6 cell starvation (to 2.8±1.3% of the nonsilenced control, n=4; Fig. 4A ). The reduction in cell size caused by serum starvation was reversed in cells transfected with MuRF1 siRNA (1.1±0.09 vs 0.56±0.04 folds in the siRNA and control starvation groups, respectively, n=8; Fig. 4B ). In contrast, transfection with nonsilencing siRNA caused no reduction in cell size (0.59±0.04 folds, n=8) or MuRF1 expression in L6 myoblasts (Fig. 4) . 
Roles of p38 MAPK in MuRF1 induction and atrophy
The treatment of L6 cells with 10 μM SB203580, an inhibitor of p38 MAPK, inhibited the MuRF1 expression upregulated in serum-starved L6 myoblasts (129.7±14.2% with SB203580 vs 219.7±10.7% after serum starvation, n=4 in each group; Fig. 5A ). DMSO (0.1%) did not affect the expression of MuRF1. The diminished cell size caused by serum starvation was reversed in cells treated with 10 μM SB203580 (0.96±0.07 folds with SB203580 vs 0.63±0.06 folds after starvation, n=8 for each group; Fig. 5B ).
DISCUSSION
In this study, we have demonstrated that the cast immobilization of the rat hindlimb increased the expression of MuRF1 in the gastrocnemius muscle. MuRF1 contains a RING-domain-related ubiquitination activity at its N-terminal end, which probably acts as an E3 ligase to regulate protein degradation, and is the major factor mediating the atrophy of a variety of cells, including skeletal muscle cells (Freemont, 2000; Centner et al., 2001 ). Ankle joint immobilization and the injection of dexamethasone in vivo increase the expression of MuRF1 mRNA and protein in skeletal muscle (Bodine et al., 2001; Benveniste et al., 2005) . Both MuRF1 and MAFbx have roles as ligases and their expression is involved in the development of skeletal muscle atrophy (Glass, 2005) . MuRF1 ubiquitinates and degrades the contractile apparatus involving troponin I and titin in the M-line region of muscles (Centner et al., 2001; Kedar et al., 2004) . These data indicate that cast immobilization (B) Effect of p38 MAPK inhibitor on cell size. The cells were starved for 12 h in serum-free medium with 0.1% DMSO or 10 μM SB203580 and the cell sizes were measured under a phase-contrast microscope (×100; n=8). *Significant differences between the starved and nonstarved control groups (p＜0.05).
can lead to the expression of MuRF1, which in turn facilitates the degradation of muscle proteins and muscle atrophy. In this study, we also confirmed that cast immobilization reduces the weight of the gastrocnemius muscle. It has been widely reported that skeletal muscle atrophy is related to a reduction in nutrients, including cell starvation, the depletion of amino acids, and other phenomena (Samarel et al., 1987; Medina et al., 1995; Thomas, 2007) . It has also been reported that the expression of MAFbx and MuRF1 is increased in cardiac cells cultured in serum-free medium (Schulze et al., 2005; Skurk, et al., 2005) . Moreover, mouse fasting leads to the expression of proteins involved in protein degradation (e.g., MuRF1) in the gastrocnemius muscle (Lecker et al., 2004) . In this study, we demonstrated for the first time that the increased expression of MuRF1 and the phosphorylation of p38 MAPK caused in cells by starvation are similar in pattern to the changes observed in gastrocnemius muscles immobilized by casts. In this study, we also found that the size of L6 myoblasts decreased significantly in serum-free medium, but this reduction was reversed in cells transfected with MuRF1 siRNA. These results show that the changes in cells starved in serum-free medium mimic the morphological and functional characteristics typical of gastrocnemius muscle treated with cast immobilization. These results therefore imply that the starvation of L6 cells in serum-free medium reflects the atrophy caused by cast immobilization via a similar pathway and should be useful in the analysis of the mechanism of atrophy in the gastrocnemius muscle at the cellular level.
It has been reported that muscle atrophy is regulated by both the Akt and p38 MAPK pathways and that the induction of MuRF1 induced by atrophy is regulated by the inhibition of Akt activation (Machida and Booth, 2005) . Moreover, the upregulation of MAFbx and MuRF1 expression in atrophied muscles is mediated by p38 MAPK and nuclear factor-κB, respectively. Nuclear factor-κB is a ubiquitous transcription factor involved in a wide variety of inflammatory and pathological processes (Zhou et al., 2001; Cai et al., 2004) . It has been widely reported that the p38 MAPK and JNK pathways are responsive to stress, such as ischemic injury, osmotic shock, ionizing radiation, cytokines, hormones, growth factors, and other stressors (Chang and Karin, 2001; Kyriakis and Avruch, 2001 ). However, the regulation of MuRF1 expression by the p38 MAPK pathway in response to skeletal muscle atrophy had not been demonstrated. In this study, we observed increased p38 MAPK activity in both the cast immobilization of the gastrocnemius muscle and serum-starved L6 myoblasts, and a p38 MAPK inhibitor abolished this increase in MuRF1 in response to serum starvation in L6 myoblasts. These results strongly suggest that the expression of MuRF1 in casted gastrocnemius muscle is mediated by the activation of p38 MAPK. Although it has been reported that an inhibitor of ERK1/2 reduced the muscle mass and elicited MuRF expression and skeletal muscle atrophy (Shi et al., 2009) , the present results demonstrate for the first time that the expression of MuRF1 in atrophic muscle is regulated by p38 MAPK. Our findings suggest that the regulator p38 MAPK may act in preventing skeletal muscle disorders, including muscle atrophy, which should constitute useful information in the development of therapeutic strategies.
In conclusion, the increase in MuRF1 expression in serum-starved L6 myoblasts was significantly attenuated by the inhibition of p38 MAPK. Moreover, the size changes in L6 myoblasts induced by serum starvation were reversed in cells transfected with MuRF1 siRNA or treated with a p38 MAPK inhibitor. From these results, we infer that the MuRF1-mediated atrophy observed in cast-immobilized rat gastrocnemius muscles is regulated by p38 MAPK.
